Comparative Pharmacology
Head-to-head clinical analysis: DIZAC versus PAXIPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIZAC versus PAXIPAM.
DIZAC vs PAXIPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dizac is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, resulting in increased chloride ion influx, neuronal hyperpolarization, and inhibition of neuronal excitability.
PAXIPAM (flurazepam) is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion conductance and producing CNS depression.
10 mg IV/IM every 4-6 hours as needed; max 40 mg/day.
5-10 mg orally every 8-12 hours as needed; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours in adults; prolonged in renal impairment (up to 20 hours in anuria), neonates, and elderly. Clinical context: Repeated dosing recommended every 4-6 hours.
Terminal elimination half-life is 30-40 hours in healthy adults; prolonged in elderly and hepatic impairment.
Renal (70-80% as unchanged drug and metabolites, primarily via glomerular filtration and active tubular secretion), biliary/fecal (15-20%)
Renal excretion of unchanged drug and glucuronide metabolites accounts for 60-70%; fecal excretion accounts for 20-30%.
Category C
Category C
Benzodiazepine
Benzodiazepine